Infants diagnosed with acute lymphoblastic leukemia (ALL) are at a higher risk of experiencing relapse after treatment. In babies under one year, a specific genetic change in the KMT2A gene can occur, causing a mutant protein that drives further development of leukemia after remission. However, a new clinical trial aimed at treating infants with recurrent ALL considers a new therapy called Revumenib that, in conjunction with chemotherapy, may be effective in targeting the KMT2A rearrangement.

In this video, Kelly Faulk, MD, a pediatric oncologist in our Center for Cancer and Blood Disorders, shares valuable information about infant ALL, KMT2A rearrangement and the clinical trial. Alongside researchers at the University of Colorado School of Medicine, Patricia Ernst, PhD, and Matthew Witkowski, PhD, are vital in determining the safety and dosage for patients and the efficacy of Revumenib with chemotherapy.

To learn more about our Center for Cancer and Blood Disorders, visit: [ Ссылка ]

Connect with Children’s Colorado:
Instagram: [ Ссылка ]
Facebook: [ Ссылка ]
Twitter: [ Ссылка ]
LinkedIn: [ Ссылка ]
Pinterest: [ Ссылка ]
Website: [ Ссылка ]

свернуть